CHERNOVASKAYA TATYANA VENIAMINOVNA,DENISOV LEV ALEXANDROVICH,RUDENKO ELENA GEORGIEVNA,KLENOVA ANGELINA VSEVOLODOVNA,MOROZOV DMITRIY VALENTINOVICH
申请号：
CO13009157
公开号：
CO6680611A2
申请日:
2013.01.18
申请国别(地区):
CO
年份:
2013
代理人:
摘要：
The Invention relates to the pharmaceutical industry and medicine, in particular the new Peg interferon conjugated derivatives and the discovery of a New functional, highly Stable interferon to polyethylene glycol with an activity of interferon alfa with reduced immunogenicity. With extensive Biological effects and Pharmaco Kinetic parameters improved General formula.Where: N - integral values of 227 10 000, so that the molecular weight of Peg is around 10 000 to 40 000 da； M - integer = 4； natural or recombinant IFN - polypeptide having the activity of IFN Alpha.Also, The Invention relates to a drug containing the Conjugate of the formula (i), Pharmaceutical compositions containing Peg IFN conjugate and therapeutically acceptable excipients, ideal for the treatment of Viral Infections and cancer, also associated diseases S with primary or secondary immunodeficiency.The Invention relates to the use of conjugate of formula (1) in medicinal products, which have antiviral, antiproliferative and immunomodulatory approaches and / or treatment of diseases associated with immunodeficiency, primary or secondary conjugate (formula (i) and the container with such Pharmaceutical composition.La invención está relacionada a la industria farmacéutica y medicina,, en particular, al nuevo PEG-interferón derivados y al descubrimiento de un conjugado nuevo funcional, altamente estable de interferón a polietileno glicol con una actividad de interferón alfa, con inmunogenicidad reducida, con efectos biológicos prolongados y parámetros fármaco-kinéticos mejorados de fórmula general.Donde:n- valores integrales de 227 a 10 000, así que el peso molecular de PEG es de alrededor de 10 000 - 40 000 Da；m - integer = 4；IFN - natural o recombinante polipéptido teniendo la actividad de IFN aIfa.También, la invención está relacionada a drogas conteniendo el declarado conjugado de la fórmula (I), composiciones farmacéuticas conteniendo PEG-IFN conjugado y terapéuticamente aceptable excipientes ide
